Novartis India (BOM:500672) Total Operating Expense: ₹635 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500672 Novartis India Ltd BOM:500672
53 GF Score
Price ₹1,647.25
GF Value ₹1,010.82
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Total Operating Expense?

Novartis India BOM:500672 -1.30% 53 Total Operating Expense is ₹635 Mil as of Jun. 2026. GuruFocus rates BOM:500672 with a GF Score™ of 53/100 and a GF Value™ of ₹1,010.82 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Novartis India's Total Operating Expense for the three months ended in Jun. 2026 was ₹136 Mil. Novartis India's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹635 Mil.

Novartis India Total Operating Expense Related Terms

Novartis India Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Novartis India's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis India Total Operating Expense Chart

Novartis India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,886.90 952.30 664.00 589.90 639.40

Novartis India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 141.00 164.50 151.50 182.40 136.20
BOM:500672
53GF Score
Novartis India Ltd BOM:500672
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis India Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹635 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹635 Mil mean?
Novartis India (BOM:500672) has a Total Operating Expense of ₹635 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novartis India and its competitors.
Is Novartis India's Total Operating Expense too high?
Novartis India's current Total Operating Expense is ₹635 Mil. Overall, Novartis India has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Total Operating Expense compare to ZTS?
Novartis India's Total Operating Expense of ₹635 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novartis India and its competitors. Novartis India's current Total Operating Expense is ₹635 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,010.82, compared to a current price of ₹1,647.25 — trading 63% above its estimated fair value. The current Total Operating Expense is ₹635 Mil. Novartis India's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Novartis India (BOM:500672), the current Total Operating Expense is ₹635 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis India (BOM:500672) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,647.25 is trading 63% above its estimated GF Value™ of ₹1,010.82. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for BOM:500672:

  • Total Operating Expense: ₹635 Mil
  • GF Value™: ₹1,010.82 vs. price of ₹1,647.25 (63% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis India Business Description

Other Exchanges NOVARTIND:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
53GF Score

Get the complete analysis for BOM:500672

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,647.25
Price
₹1,010.82
GF Value